1) Strategy & Leadership - Stryker's recovery from a cybersecurity incident is ongoing, with production ramping up to meet demand. - The company reported strong organic sales growth of 9% in Q2 2026, driven by med surg, neurotechnology, and orthopedics. - The sales force has been stabilized, and the company is optimistic about recapturing lost sales in the peripheral vascular business due to recent supply disruptions.

2) Financial & Segment Results - Adjusted EPS grew by 17.9% to $3.69, reflecting improved gross margins and operational execution. - Organic sales growth by segment: - MedSurg and Neurotechnology: 9.2% (8.9% U.S., 10.5% international) - Instruments: 8.4% (U.S. growth down from 16.3% YoY) - Endoscopy: 10.2% (strong demand across various areas) - Medical: 13.1% (led by preoperative products) - Orthopedics: 8.6% (U.S. knees grew 6.2%, hips 4.9%) - Vascular: 6.7% decline due to supply issues.

3) Operational or Product Plans - Stryker is launching several new products, including Mako RPS and Triathlon Gold, with positive early feedback. - The company is focusing on capital equipment, with a strong backlog and elevated demand for products like ProCuity beds. - The procedural environment remains stable, with no significant changes in surgical volume trends observed.

4) Guidance & Outlook / Investor Angle - Full-year guidance for organic net sales growth is narrowed to 8.3% to 9.3%, with adjusted EPS expected between $14.95 and $15.10. - The company plans to resume share repurchases, leveraging strong cash flow generation and recent valuation compression in the medtech sector. - Stryker remains committed to M&A as a primary capital allocation priority, while also considering opportunistic share buybacks.

5) Missing Information - The call did not provide specific figures on the impact of the cybersecurity incident on sales or detailed projections for the second half of the year beyond general confidence in recovery.

Bottom line: Stryker is on track for a strong year despite recent challenges, with solid growth across multiple segments and a focus on new product launches and operational improvements, making it an attractive investment opportunity for shareholders.